{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"data_sharing_plan":["IPD Sharing (as of April 2023): No"],"condition":["Colorectal Neoplasms"],"disease":["Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2397135"],"location":["United States"],"study_start_month":["2"],"keyword":["Individualized cancer vaccine","MCRC","Colorectal cancer vaccine","Rectal","Personalized cancer vaccine","Ipilimumab","Leucovorin","Bevacizumab","Personal cancer vaccine","CRC","Immunotherapy","Rectum","Colon","MSS-CRC","Atezolizumab"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","description":"The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (patient-specific vaccines) in combination with checkpoint inhibitors in addition to fluoropyrimidine/bevacizumab versus a fluoropyrimidine/bevacizumab alone as assessed by molecular response which is based on changes in circulating tumor (ct)DNA. The primary objective of the Phase 3 portion is to demonstrate clinical efficacy of the regimen as assessed by progression-free survival.","dates":{"creation":"2022-02-15"},"accession":"2397135","cross_references":{"ClinicalTrials___gov":["NCT05141721"]}}